Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety

Subramaniam Ananthan, Cheryl A. Johnson, Ronald L. Carter, Sarah D. Clayton, Kenner C. Rice, Heng Xu, Peg Davis, Frank Porreca, Richard B. Rothman

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

A series of analogues of the δ opioid receptor antagonist naltrindole (1) possessing a phenyl, phenoxy, or benzyloxy group at the 4'-, 5'-, 6'-, or - 7'-positions (4-15) and a 2-(2-pyridinyl)ethenyl group at the 5'-position (16) on the indolic benzene ring were synthesized through Fischer indolization of naltrexone. Compounds 4-16 were evaluated for their affinities in opioid receptor binding assays in rat or guinea pig brain membranes and for their opioid antagonist and agonist activities in vitro on the guinea pig ileum (GPI) and mouse vas deferens (MVD) preparations. All of the compounds displayed δ selectivity in binding to the δ, μ, and κ opioid receptors. The binding potencies of most of the compounds at the δ, μ, and κ sites, however, were lower than that of 1. Among positional isomers, the 7'-substituted compounds in general had higher affinities than 6'-, 5'-, or 4'-substituted analogues, indicating that bulky groups are tolerated better at the 7'-position than at other positions. The affinity of the compounds were also determined at putative subtypes of the δ and κ receptors: δ(cx-1) (μ-like), δ(cx-2) (δ-like), and the κ(2b) site in an attempt to identify subtype selective agents. Although none were identified, the data revealed a different rank-order of potency between μ vs δ(cx-1), δ(cx-2) vs δ, and the κ(2b) vs μ, δ, and κ1. The antagonist potencies of the compounds in the MVD were in agreement with their binding affinities at the δ site in rat brain membrane. The most potent member of the series, the 7'-phenoxy compound 14, binds to the δ site with a K(i) of 0.71 nM, shows > 40-fold δ over μ and δ over κ binding selectivity, and exhibits δ receptor antagonist potency in the MVD with a K(e) of 0.25 nM, properties which are comparable to the δ receptor affinity and antagonist potency of naltrindole (K(i) = 0.29 nM, K(e) = 0.49 nM). Interestingly, many members of the series were found to possess significant partial to full agonist activities in the MVD (6, 9, 10, 13, 16) or GPI (6, 11, 14, 15). Among the compounds studied, the highest agonist activity in the MVD was displayed by 16 (IC50 = 220 nM), and the highest agonist activity in the GPI was displayed by 14 (IC50 = 450 nM). The overall affinity and activity profile of compound 14 is, therefore, that of a nonpeptide ligand possessing mixed μ agonist/δ antagonist properties. Recently there has been considerable interest in such compounds possessing μ agonist/δ antagonist activities because of their potential therapeutic usefulness as analgesics with low propensity to produce tolerance and dependence side effects. The results of the present study suggest that morphinan derivatives related to 16 and 14 may provide useful leads for the development of potent nonpeptide ligands possessing δ agonist or mixed δ antagonist/μ agonist activities.

Original languageEnglish (US)
Pages (from-to)2872-2881
Number of pages10
JournalJournal of Medicinal Chemistry
Volume41
Issue number15
DOIs
StatePublished - Jul 16 1998

Fingerprint

naltrindole
Vas Deferens
Narcotic Antagonists
Bioassay
Opioid Receptors
Benzene
Biological Assay
Rats
Brain
Morphinans
Ligands
Membranes
Guinea Pigs
Naltrexone
Ileum
Isomers
Analgesics
Assays
Inhibitory Concentration 50
Derivatives

ASJC Scopus subject areas

  • Organic Chemistry

Cite this

Ananthan, S., Johnson, C. A., Carter, R. L., Clayton, S. D., Rice, K. C., Xu, H., ... Rothman, R. B. (1998). Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety. Journal of Medicinal Chemistry, 41(15), 2872-2881. https://doi.org/10.1021/jm980083i

Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety. / Ananthan, Subramaniam; Johnson, Cheryl A.; Carter, Ronald L.; Clayton, Sarah D.; Rice, Kenner C.; Xu, Heng; Davis, Peg; Porreca, Frank; Rothman, Richard B.

In: Journal of Medicinal Chemistry, Vol. 41, No. 15, 16.07.1998, p. 2872-2881.

Research output: Contribution to journalArticle

Ananthan, S, Johnson, CA, Carter, RL, Clayton, SD, Rice, KC, Xu, H, Davis, P, Porreca, F & Rothman, RB 1998, 'Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety', Journal of Medicinal Chemistry, vol. 41, no. 15, pp. 2872-2881. https://doi.org/10.1021/jm980083i
Ananthan, Subramaniam ; Johnson, Cheryl A. ; Carter, Ronald L. ; Clayton, Sarah D. ; Rice, Kenner C. ; Xu, Heng ; Davis, Peg ; Porreca, Frank ; Rothman, Richard B. / Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety. In: Journal of Medicinal Chemistry. 1998 ; Vol. 41, No. 15. pp. 2872-2881.
@article{404824217b9e40379e592a26b84e462a,
title = "Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety",
abstract = "A series of analogues of the δ opioid receptor antagonist naltrindole (1) possessing a phenyl, phenoxy, or benzyloxy group at the 4'-, 5'-, 6'-, or - 7'-positions (4-15) and a 2-(2-pyridinyl)ethenyl group at the 5'-position (16) on the indolic benzene ring were synthesized through Fischer indolization of naltrexone. Compounds 4-16 were evaluated for their affinities in opioid receptor binding assays in rat or guinea pig brain membranes and for their opioid antagonist and agonist activities in vitro on the guinea pig ileum (GPI) and mouse vas deferens (MVD) preparations. All of the compounds displayed δ selectivity in binding to the δ, μ, and κ opioid receptors. The binding potencies of most of the compounds at the δ, μ, and κ sites, however, were lower than that of 1. Among positional isomers, the 7'-substituted compounds in general had higher affinities than 6'-, 5'-, or 4'-substituted analogues, indicating that bulky groups are tolerated better at the 7'-position than at other positions. The affinity of the compounds were also determined at putative subtypes of the δ and κ receptors: δ(cx-1) (μ-like), δ(cx-2) (δ-like), and the κ(2b) site in an attempt to identify subtype selective agents. Although none were identified, the data revealed a different rank-order of potency between μ vs δ(cx-1), δ(cx-2) vs δ, and the κ(2b) vs μ, δ, and κ1. The antagonist potencies of the compounds in the MVD were in agreement with their binding affinities at the δ site in rat brain membrane. The most potent member of the series, the 7'-phenoxy compound 14, binds to the δ site with a K(i) of 0.71 nM, shows > 40-fold δ over μ and δ over κ binding selectivity, and exhibits δ receptor antagonist potency in the MVD with a K(e) of 0.25 nM, properties which are comparable to the δ receptor affinity and antagonist potency of naltrindole (K(i) = 0.29 nM, K(e) = 0.49 nM). Interestingly, many members of the series were found to possess significant partial to full agonist activities in the MVD (6, 9, 10, 13, 16) or GPI (6, 11, 14, 15). Among the compounds studied, the highest agonist activity in the MVD was displayed by 16 (IC50 = 220 nM), and the highest agonist activity in the GPI was displayed by 14 (IC50 = 450 nM). The overall affinity and activity profile of compound 14 is, therefore, that of a nonpeptide ligand possessing mixed μ agonist/δ antagonist properties. Recently there has been considerable interest in such compounds possessing μ agonist/δ antagonist activities because of their potential therapeutic usefulness as analgesics with low propensity to produce tolerance and dependence side effects. The results of the present study suggest that morphinan derivatives related to 16 and 14 may provide useful leads for the development of potent nonpeptide ligands possessing δ agonist or mixed δ antagonist/μ agonist activities.",
author = "Subramaniam Ananthan and Johnson, {Cheryl A.} and Carter, {Ronald L.} and Clayton, {Sarah D.} and Rice, {Kenner C.} and Heng Xu and Peg Davis and Frank Porreca and Rothman, {Richard B.}",
year = "1998",
month = "7",
day = "16",
doi = "10.1021/jm980083i",
language = "English (US)",
volume = "41",
pages = "2872--2881",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "15",

}

TY - JOUR

T1 - Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety

AU - Ananthan, Subramaniam

AU - Johnson, Cheryl A.

AU - Carter, Ronald L.

AU - Clayton, Sarah D.

AU - Rice, Kenner C.

AU - Xu, Heng

AU - Davis, Peg

AU - Porreca, Frank

AU - Rothman, Richard B.

PY - 1998/7/16

Y1 - 1998/7/16

N2 - A series of analogues of the δ opioid receptor antagonist naltrindole (1) possessing a phenyl, phenoxy, or benzyloxy group at the 4'-, 5'-, 6'-, or - 7'-positions (4-15) and a 2-(2-pyridinyl)ethenyl group at the 5'-position (16) on the indolic benzene ring were synthesized through Fischer indolization of naltrexone. Compounds 4-16 were evaluated for their affinities in opioid receptor binding assays in rat or guinea pig brain membranes and for their opioid antagonist and agonist activities in vitro on the guinea pig ileum (GPI) and mouse vas deferens (MVD) preparations. All of the compounds displayed δ selectivity in binding to the δ, μ, and κ opioid receptors. The binding potencies of most of the compounds at the δ, μ, and κ sites, however, were lower than that of 1. Among positional isomers, the 7'-substituted compounds in general had higher affinities than 6'-, 5'-, or 4'-substituted analogues, indicating that bulky groups are tolerated better at the 7'-position than at other positions. The affinity of the compounds were also determined at putative subtypes of the δ and κ receptors: δ(cx-1) (μ-like), δ(cx-2) (δ-like), and the κ(2b) site in an attempt to identify subtype selective agents. Although none were identified, the data revealed a different rank-order of potency between μ vs δ(cx-1), δ(cx-2) vs δ, and the κ(2b) vs μ, δ, and κ1. The antagonist potencies of the compounds in the MVD were in agreement with their binding affinities at the δ site in rat brain membrane. The most potent member of the series, the 7'-phenoxy compound 14, binds to the δ site with a K(i) of 0.71 nM, shows > 40-fold δ over μ and δ over κ binding selectivity, and exhibits δ receptor antagonist potency in the MVD with a K(e) of 0.25 nM, properties which are comparable to the δ receptor affinity and antagonist potency of naltrindole (K(i) = 0.29 nM, K(e) = 0.49 nM). Interestingly, many members of the series were found to possess significant partial to full agonist activities in the MVD (6, 9, 10, 13, 16) or GPI (6, 11, 14, 15). Among the compounds studied, the highest agonist activity in the MVD was displayed by 16 (IC50 = 220 nM), and the highest agonist activity in the GPI was displayed by 14 (IC50 = 450 nM). The overall affinity and activity profile of compound 14 is, therefore, that of a nonpeptide ligand possessing mixed μ agonist/δ antagonist properties. Recently there has been considerable interest in such compounds possessing μ agonist/δ antagonist activities because of their potential therapeutic usefulness as analgesics with low propensity to produce tolerance and dependence side effects. The results of the present study suggest that morphinan derivatives related to 16 and 14 may provide useful leads for the development of potent nonpeptide ligands possessing δ agonist or mixed δ antagonist/μ agonist activities.

AB - A series of analogues of the δ opioid receptor antagonist naltrindole (1) possessing a phenyl, phenoxy, or benzyloxy group at the 4'-, 5'-, 6'-, or - 7'-positions (4-15) and a 2-(2-pyridinyl)ethenyl group at the 5'-position (16) on the indolic benzene ring were synthesized through Fischer indolization of naltrexone. Compounds 4-16 were evaluated for their affinities in opioid receptor binding assays in rat or guinea pig brain membranes and for their opioid antagonist and agonist activities in vitro on the guinea pig ileum (GPI) and mouse vas deferens (MVD) preparations. All of the compounds displayed δ selectivity in binding to the δ, μ, and κ opioid receptors. The binding potencies of most of the compounds at the δ, μ, and κ sites, however, were lower than that of 1. Among positional isomers, the 7'-substituted compounds in general had higher affinities than 6'-, 5'-, or 4'-substituted analogues, indicating that bulky groups are tolerated better at the 7'-position than at other positions. The affinity of the compounds were also determined at putative subtypes of the δ and κ receptors: δ(cx-1) (μ-like), δ(cx-2) (δ-like), and the κ(2b) site in an attempt to identify subtype selective agents. Although none were identified, the data revealed a different rank-order of potency between μ vs δ(cx-1), δ(cx-2) vs δ, and the κ(2b) vs μ, δ, and κ1. The antagonist potencies of the compounds in the MVD were in agreement with their binding affinities at the δ site in rat brain membrane. The most potent member of the series, the 7'-phenoxy compound 14, binds to the δ site with a K(i) of 0.71 nM, shows > 40-fold δ over μ and δ over κ binding selectivity, and exhibits δ receptor antagonist potency in the MVD with a K(e) of 0.25 nM, properties which are comparable to the δ receptor affinity and antagonist potency of naltrindole (K(i) = 0.29 nM, K(e) = 0.49 nM). Interestingly, many members of the series were found to possess significant partial to full agonist activities in the MVD (6, 9, 10, 13, 16) or GPI (6, 11, 14, 15). Among the compounds studied, the highest agonist activity in the MVD was displayed by 16 (IC50 = 220 nM), and the highest agonist activity in the GPI was displayed by 14 (IC50 = 450 nM). The overall affinity and activity profile of compound 14 is, therefore, that of a nonpeptide ligand possessing mixed μ agonist/δ antagonist properties. Recently there has been considerable interest in such compounds possessing μ agonist/δ antagonist activities because of their potential therapeutic usefulness as analgesics with low propensity to produce tolerance and dependence side effects. The results of the present study suggest that morphinan derivatives related to 16 and 14 may provide useful leads for the development of potent nonpeptide ligands possessing δ agonist or mixed δ antagonist/μ agonist activities.

UR - http://www.scopus.com/inward/record.url?scp=0031874983&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031874983&partnerID=8YFLogxK

U2 - 10.1021/jm980083i

DO - 10.1021/jm980083i

M3 - Article

C2 - 9667975

AN - SCOPUS:0031874983

VL - 41

SP - 2872

EP - 2881

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 15

ER -